On December 17, Gluonhui reported that DaShenLin Pharmaceutical Group (603233.SH) is a leading large chain pharmacy enterprise in South China and ranks among the top in the country. Directly operated store retail is the main source of the company's revenue and profit. In recent years, the company has completed the layout in 21 provinces through "self-built + mergers + franchising." In the future, the company will focus on the development of existing stores, as there is significant potential for improvement in the profitability and operational efficiency of out-of-province stores, which will drive the company's market share growth in various provinces and cities. The initial coverage gives a "Buy" rating.